Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Long term deficiency of vitamin D in germ cell testicular cancer survivors.

Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, De Placido S, Palmieri G.

Oncotarget. 2018 Apr 20;9(30):21078-21085. doi: 10.18632/oncotarget.24925. eCollection 2018 Apr 20.

2.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

3.

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.

Buonerba C, De Placido P, Bruzzese D, Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, Perri F, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G.

Front Pharmacol. 2018 Mar 16;9:189. doi: 10.3389/fphar.2018.00189. eCollection 2018.

4.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
5.

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.

Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2.

PMID:
29437766
6.

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.

Pensabene M, Stanzione B, Cerillo I, Ciancia G, Cozzolino I, Ruocco R, Condello C, Di Lorenzo G, Giuliano M, Forestieri V, Arpino G, De Placido S, Lauria R.

BMC Cancer. 2018 Feb 6;18(1):146. doi: 10.1186/s12885-018-4054-x.

7.

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.

Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G.

Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29.

8.

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G.

Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.

9.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G.

Breast. 2018 Apr;38:86-91. doi: 10.1016/j.breast.2017.12.012. Epub 2018 Jan 4.

PMID:
29287189
10.

Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study.

Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, Lauria R, De Santo I, Conforti A, Gallo A, Nazzaro G, De Placido S, Locci M, De Placido G.

Menopause. 2018 Jun;25(6):657-662. doi: 10.1097/GME.0000000000001053.

PMID:
29286986
11.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.

J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.

PMID:
29240542
12.

PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?

Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M.

Breast Care (Basel). 2017 Oct;12(5):290-294. doi: 10.1159/000481657. Epub 2017 Oct 19. Review.

PMID:
29234247
13.

Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report.

Nunziato M, Starnone F, Lombardo B, Pensabene M, Condello C, Verdesca F, Carlomagno C, De Placido S, Pastore L, Salvatore F, D'Argenio V.

Int J Mol Sci. 2017 Nov 22;18(11). pii: E2487. doi: 10.3390/ijms18112487.

14.

The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario?

Perri F, Buono G, Schettini F, Arpino G, Bianco R, Criscitiello C, De Placido S, Giuliano M.

Anticancer Agents Med Chem. 2017 Nov 2. doi: 10.2174/1871520617666171103105247. [Epub ahead of print]

PMID:
29110627
15.

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.

Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, Pagliuca M, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G.

J Cancer. 2017 Aug 22;8(14):2663-2668. doi: 10.7150/jca.20040. eCollection 2017.

16.

Immunotherapy for penile cancer.

Buonerba C, Pagliuca M, Vitrone FM, Ascione I, Elefante I, Riccio V, Romano F, De Placido S, Di Lorenzo G.

Future Sci OA. 2017 May 2;3(3):FSO195. doi: 10.4155/fsoa-2017-0031. eCollection 2017 Aug. No abstract available.

17.

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Federico P, Daniele B, Morelli F, Bellelli T, Ferro M, De Placido S, Buonerba C.

Eur Urol Focus. 2017 Apr 8. pii: S2405-4569(17)30083-4. doi: 10.1016/j.euf.2017.03.015. [Epub ahead of print]

PMID:
28753882
18.

Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?

De Stefano A, Rosanova M, Malapelle U, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C.

Int J Biol Markers. 2017 Oct 31;32(4):e474-e477. doi: 10.5301/ijbm.5000273.

PMID:
28665451
19.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

20.

Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study.

Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, Bruzzese D, De Placido S, Arpino G.

Clin Breast Cancer. 2017 Nov;17(7):559-563. doi: 10.1016/j.clbc.2017.05.007. Epub 2017 May 19.

PMID:
28601383
21.

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2017 May 23;116(11):1425-1435. doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25.

22.

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.

Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S.

Oncologist. 2017 May;22(5):601-608. doi: 10.1634/theoncologist.2016-0246. Epub 2017 Apr 19.

23.

2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.

Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G, Trimarco B, De Placido S, Galderisi M.

Eur Heart J Cardiovasc Imaging. 2017 May 1;18(8):930-936. doi: 10.1093/ehjci/jex033.

PMID:
28379383
24.

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G.

Clin Genitourin Cancer. 2017 Oct;15(5):548-555.e3. doi: 10.1016/j.clgc.2017.02.002. Epub 2017 Feb 27.

PMID:
28325636
25.

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.

De Placido S, De Angelis C, Giuliano M, Pizzi C, Ruocco R, Perrone V, Bruzzese D, Tommasielli G, De Laurentiis M, Cammarota S, Arpino G, Arpino G.

Br J Cancer. 2017 Mar 14;116(6):821-827. doi: 10.1038/bjc.2017.24. Epub 2017 Feb 7.

26.

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G.

Front Pharmacol. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. eCollection 2016.

27.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
28.

Tumor characteristics and prognosis in familial breast cancer.

Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.

BMC Cancer. 2016 Nov 29;16(1):924.

29.

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F.

Breast. 2017 Feb;31:114-120. doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9.

30.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.

31.

Approaches for targeting cancer stem cells drug resistance.

Rosa R, D'Amato V, De Placido S, Bianco R.

Expert Opin Drug Discov. 2016 Dec;11(12):1201-1212. Epub 2016 Oct 14. Review.

PMID:
27700193
32.

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

Schettini F, Giuliano M, De Placido S, Arpino G.

Cancer Treat Rev. 2016 Nov;50:129-141. doi: 10.1016/j.ctrv.2016.09.004. Epub 2016 Sep 12. Review.

PMID:
27665540
33.

Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.

Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, De Placido S, Nazzaro G, Locci M, De Placido G.

Menopause. 2016 Oct;23(10):1108-13. doi: 10.1097/GME.0000000000000672.

PMID:
27648595
34.

The emerging role of obesity, diet and lipid metabolism in prostate cancer.

Ferro M, Terracciano D, Buonerba C, Lucarelli G, Bottero D, Perdonà S, Autorino R, Serino A, Cantiello F, Damiano R, Andras I, De Placido S, Di Lorenzo G, Battaglia M, Jereczek-Fossa BA, Mirone V, De Cobelli O.

Future Oncol. 2017 Feb;13(3):285-293. doi: 10.2217/fon-2016-0217. Epub 2016 Sep 14. Review.

35.

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer.

Pensabene M, Condello C, Carlomagno C, De Placido S, Liccardo R, Duraturo F.

Hered Cancer Clin Pract. 2016 Sep 6;14(1):18. doi: 10.1186/s13053-016-0054-5. eCollection 2016.

36.

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.

Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G.

Expert Opin Biol Ther. 2016 Nov;16(11):1387-1401. Epub 2016 Aug 5.

PMID:
27463642
37.

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.

Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.

BMC Cancer. 2016 Jul 4;16:375. doi: 10.1186/s12885-016-2414-y.

38.

Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.

Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LS, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G.

Curr Res Transl Med. 2016 Jan-Mar;64(1):15-20. doi: 10.1016/j.retram.2016.01.004. Epub 2016 Mar 2.

PMID:
27140595
39.

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.

Di Lorenzo G, Pagliuca M, Perillo T, Benincasa A, Bosso D, De Placido S, Buonerba C.

Medicine (Baltimore). 2016 Apr;95(14):e2754. doi: 10.1097/MD.0000000000002754. Review.

40.

Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.

Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L.

Cancer Treat Rev. 2016 May;46:20-6. doi: 10.1016/j.ctrv.2016.03.012. Epub 2016 Apr 1. Review.

41.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

42.

Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report.

Di Lorenzo G, Pagliuca M, Perillo T, Zarrella A, Verde A, De Placido S, Buonerba C.

Medicine (Baltimore). 2016 Feb;95(5):e2598. doi: 10.1097/MD.0000000000002598.

43.

Biomarkers in localized prostate cancer.

Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, Deliu VM, Ditonno P, Perdonà S, Autorino R, Coman I, De Placido S, Di Lorenzo G, De Cobelli O.

Future Oncol. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15. Review.

44.

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.

Di Lorenzo G, Bracarda S, Gasparro D, Gernone A, Messina C, Zagonel V, Puglia L, Bosso D, Dondi D, Sonpavde G, Lucarelli G, De Placido S, Buonerba C.

Medicine (Baltimore). 2016 Jan;95(2):e2299. doi: 10.1097/MD.0000000000002299.

45.

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.

Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, Ferro M, Benincasa A, Ribera D, Lucarelli G, De Cobelli O, Sonpavde G, De Placido S.

Medicine (Baltimore). 2015 Dec;94(51):e2297. doi: 10.1097/MD.0000000000002297.

46.

Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.

Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D, Tocchetti CG.

Biomed Res Int. 2015;2015:138148. doi: 10.1155/2015/138148. Epub 2015 Oct 25. Review.

47.

Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.

Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S, Bufo P, Maiorano E, Ribatti D, Ranieri E, Gigante M, Gesualdo L, Ferro M, de Cobelli O, Buonerba C, Di Lorenzo G, De Placido S, Palazzo S, Bettocchi C, Ditonno P, Battaglia M.

Medicine (Baltimore). 2015 Nov;94(46):e2117. doi: 10.1097/MD.0000000000002117.

48.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
49.

Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review.

Di Lorenzo G, Federico P, De Placido S, Buonerba C.

Crit Rev Oncol Hematol. 2015 Dec;96(3):534-41. doi: 10.1016/j.critrevonc.2015.07.004. Epub 2015 Jul 20. Review.

PMID:
26520458
50.

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.

Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditonno P, Perdonà S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D.

Medicine (Baltimore). 2015 Oct;94(42):e1861. doi: 10.1097/MD.0000000000001861.

Supplemental Content

Loading ...
Support Center